Hyris
Following the launch of its Marketplace in 2022, Hyris continues to leverage the AI capabilities of its genetic testing platform, renowned for its adaptability, to support both researchers and kit developers worldwide. New onboarding programs enable emerging players to accelerate their go-to-market, as well as established manufacturers and diagnostic providers to integrate their portfolio with ease, maximizing their cost-per-value strategy.
LONDON, UK / ACCESSWIRE / September 27, 2023 / In the age of early mass dissemination of accessible AI solutions, many specialists and researchers from different scientific, technical and academic fields claim that AI has not yet gone far enough. According to a recent Editorial published in Nature, several research fields which need accurate and accessible data won't achieve their full potential until they integrate adequate machine-learning systems.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.With Hyris both established and emerging test developers can optimize their go-to-market by leveraging the power of AI.
Even if AI tools promise a disruption in the way researchers seek and synthesize useful new substances and tests, we are far from a wholesale revolution yet, also because of the lack of data available to feed centralized AI systems. This poses several challenges to researchers and kit developers in designing and delivering new testing solutions.
Hyris keeps true to its vision, to democratize genetics and health insights, marking a new stage in its partnership policies with newfangled onboarding programs specifically designed to further support researchers and kit developers at every stage.
"Genetic test developing and onboarding has always been faced with inherent challenges, from resource staffing to competence integration, from research funding to ensuring adequate testing volumes," states Angelica Baccanelli, Head of Quality & Regulation at Hyris. "Adapting to variability in the compliance environment, applying requirements to molecular assays, and developing the proper documentation for the go-to-market can all pose additional risks."
Amongst many challenges, technological access gaps are still the greatest hindrance to the development of new solutions across different industries. Hyris stands to change this for the better, by leveraging the AI capabilities of its unique genetic testing platform, renowned worldwide for its AI capabilities together with its unique features of portability, accessibility and versatility.
"Researchers and kit developers know well how hard delivering new analytical solutions can be," continues Baccanelli. "That's why we increased our commitment to support both emerging players and established manufacturers performing beyond their current analytical capability via new onboarding programs." Baccanelli goes on, depicting the advantages of such an inclusive approach. "We provide access to our technology and support developers through various stages of the development of new tests via proper education and technical assistance. This win-win approach enables any player to quickly integrate their portfolio with new products and solutions, maximizing their cost per value strategy."
Hyris's Onboarding strategy is proving successful across many industries. Such is the case of Luminis, Water Technologies, a leader in microbiome profiling and treatment solutions, which embraced Hyris' Program to bring on-site qPCR diagnostics to the aquaculture industry, enabling customers to quickly and accurately test for pathogens, viruses, and bacteria, ultimately improving their operations' overall safety and productivity in such industry. Luminis adopted the Hyris system to develop new qPCR diagnostics kits, enabling its customers to perform genetic analysis on-site rather than sending samples to a lab, significantly reducing turnaround time and allowing for more informed decision-making. Additionally, on-site testing eliminates the need for expensive lab equipment, and operators can now perform testing with minimal training.
"The benefits of on-site qPCR diagnostics are numerous," explains Lorenzo Colombo, CTO at Hyris, "ensuring faster turnaround time and reduced costs, compared to centralized diagnostic systems. On the other hand, the downsides of such an approach have been the lack of accuracy and the complexity of on-site technologies, making this approach less suitable for day-to-day operations until now. We fixed all these problems, providing highly accurate results whilst requiring minimal training to operate. Hyris can really be used in any setting, even under the harshest conditions."
Hyris' distributed technology allows the identification of new and arising needs, even from decentralized areas: this, in turn, enables the design and deployment of fitting solutions at a very early stage of any diagnostic trend, throughout various diverse use cases. Kit developers and lab specialists can now truly collaborate, tapping into different levels of data analysis in real-time to bring innovative tests with superior quality and increased fitness to market; dressing on the cake, all the more quickly and efficiently.
"Too often, centralized diagnostic paradigms risk overlooking local needs, preventing benefits from being shared equitably," sums up Stefano Lo Priore, co-founder and CEO at Hyris. "This also poses an ethical question, as innovations often fail to benefit those who need them most. Reliable portable diagnostic systems are key to building new capabilities for established and emerging diagnostic service providers. By helping others to deliver their solutions, we also fulfil our mission, generating a much wider impact worldwide."
The new Onboarding Programs are contributing to making Hyris the first choice for testing labs, test developers, and researchers looking to bring on specific tests involving smaller sample arrays, reduced time to results, and increased efficiencies and profitability.
To discover how to perform beyond your current diagnostic capability, feel free to contact a Hyris expert at info@hyris.net.
Contact Information
Gabriele Salaris
Global Experience Manager
gabriele.salaris@hyris.net
+39 345 555 3379
SOURCE: Hyris
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/787258/hyris-supports-researchers-and-developers-to-launch-testing-kits-via-new-onboarding-programs
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence23.12.2024 08:00:00 CET | Press release
Matrix streamlines document processing by cutting manual labor and operational costs, using AI agents in the enterprise. LONDON, GB / ACCESSWIRE / December 23, 2024 / Today, Beyond Work, an enterprise AI company, announced the record-setting results of Matrix, a novel memory-augmented AI framework for automating business document processing. Developed in collaboration with researchers from Penn State University, Oregon State University, and Kuehne+Nagel, one of the world's largest logistics providers, Matrix addresses the complex, time-intensive task of extracting transport references from Universal Business Language (UBL) invoices.MATRIX Results Comparing the success rates of four methods (CoT, Two-agent, Reflexion, Matrix) across GPT-4o-mini and GPT-4o, with Matrix achieving the highest performance. By harnessing an iterative, memory-centric learning strategy, Matrix achieves a 30.3% improvement over chain-of-thought prompting, outperforms a standard Large Language Model agent by 35.
Brightline Interactive Successfully Delivers A Scalable Immersive Simulation To A Global Government Service Integrator, Positioning Itself As A Leading Operating System For Processing And Visualizing Complex Information In 3D Space23.12.2024 07:00:00 CET | Press release
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, today announced that its subsidiary company Brightline Interactive, LLC ("BLI") successfully delivered a paid for advanced immersive simulation through its cutting-edge middleware platform - SpatialCore - to a large government services integrator ("GSI"). Leveraging the power of SpatialCore's spatial computing and AI platform, BLI was able to create a sophisticated spatial simulation in record time, setting what we believe has the potential to become a new industry standard. This initial simulation project was developed with the goal of allowing the GSI to gather simulation needs from others and to then add to this build, or for further deployment, in a cost effective and scalable manner. Tyler Gates, Genera
MicroVision Increases Production Capacity to Meet Anticipated Demand19.12.2024 09:20:00 CET | Press release
REDMOND, WA / ACCESSWIRE / December 19, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced that it has increased production capacity for its MOVIA L sensor to meet anticipated demand from the industrial sector. Building on the relationship with its existing automotive Tier 1 manufacturing partner, MicroVision expects output of MOVIA L sensors for 2025 to significantly increase compared to 2024. The continued acceleration of production capacity throughout 2025 will result in a reduced average cost per sensor, while maintaining a high-quality product suitable for industrial applications. "Securing this production capacity is critical to support high-volume orders from industrial customers, so we feel good closing out the year with this commitment in hand," said Sumit Sharma, Chief Executive Officer. "We are pleased with this scaling, particularly from a cost perspective, and our Tier 1 automotive supplier, ZF, i
Brightline Interactive Enters into an Agreement with the U.S. Navy for an Immersive, AI-Driven Simulator System19.12.2024 07:00:00 CET | Press release
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, today announced that its subsidiary company Brightline Interactive, LLC ("BLI") has entered into an initial six figure dollar contract with the U.S. Navy for an Immersive Simulator, to be delivered in the first half of 2025. Tyler Gates, General Manager of BLI and Chief Futurist of Glimpse, commented: "Powered by BLI's cutting-edge spatial computing platform ("SpatialCore"), we have created a game-changing technology that pushes the boundaries of what's possible via the integration of AI and Spatial Computing. The Immersive Simulator system seamlessly integrates AI into both the full motion simulation and the spatial computing environments in which they operate, offering unparalleled realism, responsiveness,
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP19.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing of new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. Building upon the positive International Preliminary Report on Patentability (IPRP) issued by the European Patent Office (EPO) in September 2024, BioNxt has initiated national-level filings in key jurisdictions, including the United States, Canada, Europe, and Japan. These patents are designed to protect the Company's proprietary sublingual formulations of anticancer drugs repurposed for the treatment of conditions such as Multiple Sclerosis (MS). "Securing robust intellectual property rights across major markets is a critical component of our strategy to bring innovative, patien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom